Miller T P, Vance R B, Ahmann F R, Rodney S R
Cancer Treat Rep. 1986 Sep;70(9):1101-4.
Ninety-seven previously untreated patients with metastatic non-small cell lung cancer were treated with combination chemotherapy consisting of mitomycin (10 mg/m2) on Day 1, cisplatin (50 mg/m2) on Days 1 and 22, and vindesine (3 mg/m2) on Days 1 and 22 (MiPE). MiPE was repeated at 6-week intervals until disease progression or unacceptable toxicity. The overall response rate was 33%. There were seven complete responses (7%) and 25 partial responses (26%). The median progression-free interval for responding patients was 7 months. Median survival for all patients was 5 months, with 16% surviving 1 year. One patient died from sepsis while neutropenic. The results with MiPE treatment for patients with non-small cell lung cancer compare favorably to other mitomycin-vinca combinations previously tested in the Southwest Oncology Group.
97例先前未接受过治疗的转移性非小细胞肺癌患者接受了联合化疗，具体方案为第1天给予丝裂霉素（10 mg/m²）、第1天和第22天给予顺铂（50 mg/m²）、第1天和第22天给予长春地辛（3 mg/m²）（MiPE方案）。MiPE方案每6周重复一次，直至疾病进展或出现不可接受的毒性。总缓解率为33%。有7例完全缓解（7%）和25例部分缓解（26%）。缓解患者的无进展生存期中位数为7个月。所有患者的中位生存期为5个月，16%的患者存活1年。1例患者在中性粒细胞减少时死于败血症。MiPE方案治疗非小细胞肺癌患者的结果与西南肿瘤协作组之前测试的其他丝裂霉素-长春花属植物联合方案相比更具优势。
